- Post-Effective Amendment to an S-8 filing (S-8 POS)
12 3월 2009 - 7:03PM
Edgar (US Regulatory)
As
filed with the Securities and Exchange Commission on March 11, 2009
Registration
No. 333-147248
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
POST-EFFECTIVE
AMENDMENT NO. 1 TO
FORM
S-8
REGISTRATION
STATEMENT
UNDER
THE SECURITIES
ACT
OF 1933
SYNVISTA
THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
13-3304550
|
(State
or other jurisdiction
|
(IRS
Employer
|
of
incorporation or organization)
|
Identification
Number)
|
221
West Grand Avenue
Montvale,
New Jersey
(Address
of Principal Executive Offices)
|
07645
(Zip
Code)
|
|
|
SYNVISTA
THERAPEUTICS, INC. 2005 STOCK PLAN
|
(Full
title of the plan)
|
Noah
Berkowitz, M.D., Ph.D.
President
and Chief Executive Officer
|
Copies
to:
Megan
N. Gates, Esq.
|
Synvista
Therapeutics, Inc.
|
Mintz,
Levin, Ferris, Glovsky & Popeo, P.C.
|
221
West Grand Avenue
|
One
Financial Center
|
Montvale,
NJ 07645
|
Boston,
MA 02111
|
(201)
934-5000
|
(617)
542-6000
|
(Name,
address, including zip code, and telephone
number,
including area code, of agent for service)
|
|
DEREGISTRATION
OF UNSOLD SECURITIES
On November 9, 2007, Synvista
Therapeutics, Inc. (the “Company”) filed a registration statement on Form S-8
(File No. 333-147248) (the “Registration Statement”). The
Registration Statement registered a total of 1,060,000 shares of the Company’s
common stock, par value $0.01 per share (the “Common Stock”), to be issued
pursuant to the Company’s 2005 Stock Plan. This offering has been
terminated because the Company intends to deregister its Common Stock under the
Securities Exchange Act of 1934, as amended. Consequently, in
accordance with an undertaking made by the Company in the Registration Statement
to remove from registration, by means of a post-effective amendment, any of the
securities that remain unsold at the termination of the offering, the Company
hereby removes from registration the securities of the Company that are
registered but unsold under the Registration Statement.
SIGNATURES
Pursuant to the requirements of the
Securities Act of 1933, the registrant certifies that it has reasonable grounds
to believe that it meets all the requirements for filing on Form S-8 and has
duly caused this Post-Effective Amendment No. 1 to its Registration Statement to
be signed on its behalf by the undersigned, thereunto duly authorized, in the
City of Montvale, State of New Jersey on March 11, 2009.
|
SYNVISTA
THERAPEUTICS, INC.
|
|
|
|
/s/ Noah Berkowitz, M.D.,
Ph.D.
|
|
Noah
Berkowitz, M.D., Ph.D.
|
|
President
and Chief Executive Officer
|
Pursuant to the requirements of the
Securities Act of 1933, this Post-Effective Amendment No. 1 to the Registration
Statement has been signed by the following persons in the capacities and on the
dates indicated.
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/ Noah Berkowitz, M.D.,
Ph.D.
|
|
President,
Chief Executive
|
|
March
11, 2009
|
Noah
Berkowitz, M.D., Ph.D.
|
|
Officer
and Director
|
|
|
|
|
|
|
|
/s/ Wendy A. Milici
|
|
Principal
Financial Officer and
|
|
March
11, 2009
|
Wendy
A. Milici
|
|
Principal
Accounting Officer
|
|
|
|
|
|
|
|
/s/ John F. Bedard
|
|
Director
|
|
March
11, 2009
|
John
F. Bedard
|
|
|
|
|
|
|
|
|
|
/s/ William Federici
|
|
Director
|
|
March
11, 2009
|
William
Federici
|
|
|
|
|
|
|
|
|
|
/s/ Mary C. Tanner
|
|
Director
|
|
March
11, 2009
|
Mary
C. Tanner
|
|
|
|
|
|
|
|
|
|
/s/ Wayne P. Yetter
|
|
Director
|
|
March
11, 2009
|
Wayne
P. Yetter
|
|
|
|
|
S.Y. Bancorp (AMEX:SYI)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
S.Y. Bancorp (AMEX:SYI)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024
Synvista Therapeutics, (아메리카 증권거래소)의 실시간 뉴스: 최근 기사 0
More News Articles